News | October 16, 2023
ImmunoACT announces the approval of India's first CAR-T cell therapy 'NexCAR19'
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
CMOs showed an increasing reluctance to take on debt in 2022
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
Indian government seeks to promote collaboration with stakeholders and harness potential for achieving growth and development of sector
The Indian pharmaceutical industry includes a network of 3,000 drug companies and 10,500 manufacturing units. It is projected to reach a value of US$ 130 billion by 2030
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
Julian Collins, Jana Windt and Michiel Stork join biopharma company’s leadership team
Subscribe To Our Newsletter & Stay Updated
